AbbVie Inc. diskutieren

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Morgan Stanley from $189.00 to $193.00. They now have an "overweight" rating on the stock.

AbbVie Inc. (NYSE: ABBV) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $170.00 price target on the stock, up previously from $160.00.

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Morgan Stanley from $193.00 to $196.00. They now have an "overweight" rating on the stock.

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Raymond James from $177.00 to $181.00. They now have an "outperform" rating on the stock.

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Barclays PLC from $170.00 to $175.00. They now have an "overweight" rating on the stock.

AbbVie Inc. (NYSE: ABBV) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Barclays PLC from $175.00 to $185.00. They now have an "overweight" rating on the stock.

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Raymond James from $181.00 to $189.00. They now have an "outperform" rating on the stock.

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at BMO Capital Markets from $187.00 to $195.00. They now have an "outperform" rating on the stock.

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Truist Financial Co. from $180.00 to $195.00. They now have a "buy" rating on the stock.

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Guggenheim from $188.00 to $190.00. They now have a "buy" rating on the stock.

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Barclays PLC from $185.00 to $195.00. They now have an "overweight" rating on the stock.

AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at BMO Capital Markets from $195.00 to $180.00. They now have an "outperform" rating on the stock.

AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at Barclays PLC from $195.00 to $187.00. They now have an "overweight" rating on the stock.

AbbVie Inc. (NYSE: ABBV) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $200.00 price target on the stock.

AbbVie Inc. (NYSE: ABBV) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating. They now have a $185.00 price target on the stock.

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Piper Sandler from $185.00 to $190.00. They now have an "overweight" rating on the stock.

AbbVie Inc. (NYSE: ABBV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $200.00 price target on the stock.

AbbVie is a pharmaceutical powerhouse that continues to impress. Their recent dividend hike and leadership changes signal a company focused on shareholder value and long-term growth. With exciting new indications for their blockbuster drug Skyrizi, AbbVie is positioning itself for continued success in the immunology space. While the current stock price may seem high, I believe the company's strong pipeline, diversified revenue streams, and shareholder-friendly initiatives make it a compelling investment opportunity. AbbVie is a well-run, innovative pharma that should reward investors who are willing to hold for the long term.

AbbVie is a diversified pharmaceutical company with a strong pipeline and steady dividend payouts. Their recent FDA approval for a new Skyrizi indication and the appointment of a new lead independent director demonstrate the company's commitment to innovation and strong corporate governance. While the stock is currently trading at a high valuation, I believe the long-term growth prospects and steady dividend make AbbVie an attractive investment option for those with a longer-term horizon. The company's proven track record of successful drug launches and effective capital allocation suggest they are well-positioned to continue delivering value for shareholders.